Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
Halime Nayır Büyükşahin,Nagehan Emiralioğlu,Ebru Yalçın,Velat Şen,Hadice Selimoğlu Şen,Hüseyin Arslan,Azer Kılıç Başkan,Fatma Betül Çakır,Cem Fırat Koray,Aslı İmran Yılmaz,Fatih Ercan,Derya Ufuk Altıntaş,Mahir Serbes,Özlem Keskin,Elif Arık,Figen Gülen,Meral Barlık,Oğuz Karcıoğlu,Ebru Damadoğlu,Mehmet Köse,Ali Ersoy,Ayşen Bingöl,Erdem Başaran,Eylül Pınar Çakır,Ayşe Tana Aslan,Yakup Canıtez,Merve Korkmaz,Ali Özdemir,Koray Harmancı,Şule Selin Soydaş,Melih Hangül,Hasan Yüksel,Gizem Özcan,Pervin Korkmaz,Mehmet Kılıç,Zeynep Gökçe Gayretli Aydın,Gönül Çaltepe,Demet Can,Sibel Doğru,Gökçen Kartal Öztürk,Ayşe Süleyman,Erdem Topal,Beste Özsezen,Mina Hızal,Ezgi Demirdöğen,Hamza Ogun,Şermin Börekçi,Hakan Yazan,Erkan Çakır,Tuğba Şişmanlar Eyüboğlu,Nazan Çobanoğlu,Güzin Cinel,Sevgi Pekcan,Uğur Özçelik,Deniz Doğru
DOI: https://doi.org/10.1002/ppul.27051
IF: 4.0899
2024-05-23
Pediatric Pulmonology
Abstract:Introduction Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non‐eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the 'Vertex treatment‐Finder' on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z‐score, CF‐associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p = .010), lower median height z‐scores (−0.87 vs. −0.55, p
pediatrics,respiratory system